Molecular testing approaches such as next-generation sequencing (NGS) are outshining more traditional IVD products such as immunoassays with nearly triple the growth rate of the overall market, according to a new report from healthcare research firm Kalorama Information.

https://www.labpulse.com/index.aspx?sec=sup&sub=gen&pag=dis&ItemID=800176